CytomX director granted 59,000 stock options

CytomX Therapeutics director Su Zhen received a grant of stock options covering 59,000 shares of common stock.

Rhea-AI Filing Summary

CytomX Therapeutics director Su Zhen received a grant of stock options covering 59,000 shares of common stock. The options were awarded at an exercise price of $2.96 per share and are held directly. Following this grant, Su Zhen holds stock options for 59,000 shares.

According to the vesting terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting, assuming continuous service as a director through that vesting date.

Insider Trade Summary

Grant/Award: 59,000 shares

Grant/Award 1 txn

Insider Su Zhen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	59,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 59,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Key Figures

Options granted: 59,000 options Exercise price: $2.96 per share Underlying shares: 59,000 shares +2 more

5 metrics

Options granted 59,000 options Stock Option (Right to Buy) grant to Su Zhen

Exercise price $2.96 per share Strike price for Su Zhen’s 59,000 options

Underlying shares 59,000 shares Common stock underlying the option grant

Post-grant options held 59,000 options Total options held following this transaction

Expiration date June 16, 2036 Option expiration for Su Zhen’s grant

Key Terms

Stock Option (Right to Buy), exercise price, derivative securities, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" on the derivative line"

exercise price financial

"conversion_or_exercise_price: "2.9600" as the exercise price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"transaction_type: "derivative" describing the option grant transaction"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vesting financial

"100% of the shares subject to the option shall vest in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"assuming continuous service as a director until such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CytomX Therapeutics (CTMX) director Su Zhen report on this Form 4?

The Form 4 reports that director Su Zhen received a grant of stock options for 59,000 shares of CytomX common stock. These options are a compensation-related award and are not an open-market purchase or sale of existing shares.

How many CytomX (CTMX) stock options did Su Zhen receive and at what price?

Su Zhen received stock options covering 59,000 shares of CytomX common stock with an exercise price of $2.96 per share. This means Su Zhen can buy up to 59,000 shares at $2.96 once the options are vested and exercisable.

When do Su Zhen’s CytomX (CTMX) stock options vest?

All 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting. Vesting requires Su Zhen to remain in continuous service as a director until that date.

Is Su Zhen buying or selling CytomX (CTMX) shares in this Form 4?

This Form 4 does not show a market buy or sell of CytomX shares. It records a grant of stock options as compensation, classified as an acquisition of derivative securities rather than an open-market transaction in the company’s common stock.

How many CytomX (CTMX) options does Su Zhen hold after this transaction?

After the reported grant, Su Zhen holds stock options for 59,000 shares of CytomX common stock. This figure reflects the total derivative securities for this option award shown in the filing’s post-transaction holdings field.

What type of security is involved in Su Zhen’s CytomX (CTMX) Form 4?

The security involved is a “Stock Option (Right to Buy)” with an underlying security of CytomX common stock. Each option gives the right to purchase one share at $2.96, subject to the vesting schedule described in the filing’s footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:53 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Su Zhen

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/17/2026		A		59,000		(1)	06/16/2036	Common Stock	59,000	$0	59,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Zhen Su	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)